Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04314869
Other study ID # TUX2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 23, 2020
Est. completion date December 2025

Study information

Verified date November 2020
Source Hospital Clinic of Barcelona
Contact Mariona Rius, MD
Phone 932275400
Email marius@clinic.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Absolut uterine factor, meaning the absence of uterus, represents a cause for sterility without the possibility of a present treatment. The uterine factor affects millions of women and may be due to congenital problems, such as the Muller anomalies (Mayer Rockitansky Syndrome) or acquired by previous hysterectomy or intrauterine adhesions (Asherman's Syndrome). The uterine transplant would represent the only possibility for patients with an absolute uterine factor to achieve both genetic and gestational maternity.


Description:

To obtain by laparoscopy a viable uterus for transplantation from a living donor is feasible. The laparoscopic procedure increases safety and provides the benefits of minimally invasive surgery to the grafting technique already described by laparotomy. The objective of the present study is to develop a pilot program in the transplant of a living donor. We include 5 pairs of uterine donor-transplant recipients indicated for sterility by absolute uterine factor due to Mayer Rokitansky Syndrome. Patients will undergo surgery for this transplant and after 6 months of it with correct function of the graft, embryos will be transferred in order to achieve pregnancy. C-section will be performed for delivery. The attempt of two gestations (if there are sufficient cryopreserved embryos for a second gestation) and withdrawing the graft (hysterectomy) and, therefore, immunosuppression is agreed.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 2025
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria Recipient: - Patient with sterility for absolute uterine factor (malformation or previous surgery for benign processes). - Age <40 years. - Absence of pathology that contraindicates a complex surgical process, immunosuppression or gestation. - Positive results to the IVF cycle prior to the surgery, obtaining quality embryos. - Acceptance to participate in the study signing the informed consent. Exclusion Criteria Recipient: - Medical or surgical pathology that contraindicates a complex pelvic surgical procedure. - Medical conditions that contraindicate, may aggravate or complicate the immunosuppressor treatment, such as neoplastic or preneoplasic diseases, chronic infectious diseases, autoimmune diseases, renal or liver failure. - Medical or surgical pathology that contraindicates pregnancy. - Anatomic alterations or vascular pathology that might difficult the vascular anastomosis: severe endometriosis, pelvic kidney, severe adherence syndrome or others. - Uncontrolled psychopathology. Inclusion Criteria donor: - Age <65 years. - First- or second-degree relatives. - Completed reproductive desire. - History of previous pregnancies and births. - Absence of associated pathology that contraindicates prolonged and complex laparoscopic surgery (pneumopathies, heart disease, morbid obesity, …). - Acceptance to participate in the study signing the informed consent Exclusion Criteria donor: - Potential future pregnancy desire. - Surgery for the treatment of gender identity disorder. - Infections: HIV or risk group, HBV-DNA and / or HBsAg positive, positive HCV, active bacterial sepsis, infections with multi-resistant bacteria, active tuberculosis or incomplete treatment of the same, Chagas disease, untreated active viral infections. - Active malignant cancer of any location, except skin basal cell carcinoma. Treated cancer without current evidence of illness but with a follow-up of less than 5 years. - Benign pelvic pathology: uterine fibroids, uterine malformations, severe endometriosis, severe adherence syndrome. - Vascular pathology: malformations, atheromatosis, hypertensive or diabetic vasculopathy, connective tissue disease with vascular involvement. - Premalignant pelvic pathology: pre-invasive cervical and/or vaginal, endometrial hyperplasia. - BRCA mutation carriers or genes related to Lynch syndrome. - History of implantation failure or multiple abortions of unknown cause. - Contraindications for the surgical procedure of donation through laparoscopy: diabetes mellitus, liver disease, nephropathy, heart disease, pneumopathy, morbid obesity or high-risk cardiovascular factors.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Uterus transplantation
Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.

Locations

Country Name City State
Spain Hospital Clinic Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Hospital Clinic of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of grafts obtained by laparoscopy It is feasible to obtain the graft by laparoscopy 2 years
Secondary Number of healthy newborns A healthy newborn after C-section 5 years
See also
  Status Clinical Trial Phase
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Completed NCT02522806 - Endometrial Local Injury Before First IVF : Evaluation of Pregnancy Rate N/A
Recruiting NCT05518175 - Patient-centered Outcomes After Permanent Female Sterilization Procedure(POPS Trial) N/A
Recruiting NCT05279560 - Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation N/A
Completed NCT04188444 - Prothrombotic Biomarkers and Ovarian Stimulation
Completed NCT03788421 - Comparison Between 2 Techniques for Bilateral Salpingectomy N/A
Completed NCT04809428 - vNOTES in Elective Bilateral Salpingectomy for Sterilization
Recruiting NCT06434233 - Opioid Use After Laparoscopic Salpingectomy N/A